A carregar...
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. W...
Na minha lista:
Publicado no: | Lancet HIV |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Elsevier B.V
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5555436/ https://ncbi.nlm.nih.gov/pubmed/28495562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(17)30065-6 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|